Inmed Pharmaceuticals Inc (INM) Stock Price, Quote & News

Company Profile

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products inc...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 604 669 7207

Fax: 778 945 6800

Website: www.inmedpharma.com

Address:

885 West Georgia Street, Suite 1445, Vancouver, Canada

Bulltrader988 Sep. 6 at 8:43 PM

$INM next week: "... a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that the Company will be participating in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025, in New York. During the conference, members of InMed's management team will also be conducting one-on-one meetings with investors. Additionally a corporate presentation from the Company will be available online. In the presentation, Mr. Michael Woudenberg, InMed's Chief Operating Officer, will highlight updates and progress of InMed's pipeline including recent data from the Company's leading pharmaceutical program INM-901 in the treatment of Alzheimer's, that was recently presented at Alzheimer's Association International Conference (AAIC) 2025, the world's leading forum for Alzheimer's disease and dementia research..." 👃👀 https://www.newsfilecorp.com/release/265322

0 · Reply

Bulltrader988 Sep. 5 at 6:47 PM

$INM 👃👀 https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-to-showcase-pipeline-progress-at-global-investment-conference?utm_source=webullapp.com&utm_medium=referral

0 · Reply

newsfile_corp Sep. 5 at 6:02 PM

https://nfne.ws/265322 $INM @inmedpharma #Alzheimer39s #cannabinoids #inm #inmed #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharma

0 · Reply

Bulltrader988 Sep. 5 at 5:56 PM

$INM "...today announced that the Company will be participating in the H.C. Wainwright 27th Annual Global Investment Conference in New York. During the conference, members of InMed's management team will also be conducting one-on-one meetings with investors. Additionally a corporate presentation from the Company will be available online.. In the presentation, Mr. Michael Woudenberg, InMed's Chief Operating Officer, will highlight updates and progress of InMed's pipeline including recent data from the Company's leading pharmaceutical program INM-901 in the treatment of Alzheimer's, that was recently presented at Alzheimer's Association International Conference (AAIC) 2025, the world's leading forum for Alzheimer's disease and dementia research..." 👃👀 https://www.stocktitan.net/news/INM/in-med-to-participate-in-the-h-c-wainwright-27th-annual-global-92o3h1q9xztx.html

0 · Reply

Space0 Sep. 3 at 4:05 AM

$INM we need some good news

0 · Reply

ZURN999 Aug. 28 at 4:16 PM

$INM InMed presents INM-901 data at 2025 Alzheimer’s Association International Conference https://ow.ly/MZxg50WNfpr

0 · Reply

Cheriebomb Aug. 26 at 8:05 PM

$INM News?

0 · Reply

Bulltrader988 Aug. 22 at 6:20 PM

$INM when will we get new news? 👃👀

0 · Reply

mhaven2020 Aug. 19 at 2:21 PM

$CGTX $GDRX $INM $OPEN. here for the week at least.

1 · Reply

Space0 Aug. 19 at 6:58 AM

$INM Why are new tweets not showing up?

0 · Reply

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Jul 28, 2025, 7:00 AM EDT - 6 weeks ago

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

Jun 27, 2025, 7:00 AM EDT - 2 months ago

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Jun 25, 2025, 8:00 AM EDT - 2 months ago

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Jun 24, 2025, 7:00 AM EDT - 2 months ago

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

Jun 13, 2025, 4:30 PM EDT - 3 months ago

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

May 12, 2025, 6:00 PM EDT - 4 months ago

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 12, 2025, 6:54 PM EST - 7 months ago

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 3, 2025, 7:30 AM EST - 7 months ago

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

Jan 22, 2025, 7:30 AM EST - 8 months ago

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

Jan 21, 2025, 7:30 AM EST - 8 months ago

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

Dec 18, 2024, 8:00 PM EST - 9 months ago

InMed Announces Results of 2024 Annual General Meeting

Dec 17, 2024, 4:56 PM EST - 9 months ago

InMed Enters Into Standby Equity Purchase Agreement

Nov 19, 2024, 7:30 AM EST - 10 months ago

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

Nov 14, 2024, 4:45 PM EST - 10 months ago

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

Nov 8, 2024, 4:44 PM EST - 10 months ago

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

Nov 5, 2024, 8:30 AM EST - 11 months ago

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

Oct 28, 2024, 7:30 AM EDT - 11 months ago

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

Oct 24, 2024, 8:00 AM EDT - 11 months ago

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

Oct 22, 2024, 8:00 AM EDT - 11 months ago

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

Sep 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

Sep 20, 2024, 4:30 PM EDT - 1 year ago

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

Aug 21, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

Aug 20, 2024, 10:10 AM EDT - 1 year ago

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

Aug 20, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

Jul 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

Jun 10, 2024, 5:18 PM EDT - 1 year ago

InMed to Present at the Emerging Growth Conference

May 14, 2024, 8:30 AM EDT - 1 year ago

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

Apr 18, 2024, 8:00 AM EDT - 1 year ago

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

Apr 16, 2024, 8:00 AM EDT - 1 year ago

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

Apr 4, 2024, 8:00 AM EDT - 1 year ago

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

Mar 20, 2024, 8:30 AM EDT - 1 year ago

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Feb 13, 2024, 5:41 PM EST - 1 year ago

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

Feb 9, 2024, 8:00 AM EST - 1 year ago

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

Jan 18, 2024, 4:41 PM EST - 1 year ago

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

Jan 16, 2024, 8:00 AM EST - 1 year ago

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

Dec 19, 2023, 6:03 PM EST - 1 year ago

InMed Announces Results of 2023 Annual General Meeting

Nov 14, 2023, 8:04 AM EST - 1 year ago

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

Nov 2, 2023, 8:00 AM EDT - 2 years ago

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

Oct 26, 2023, 7:15 PM EDT - 2 years ago

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

Oct 24, 2023, 4:38 PM EDT - 2 years ago

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

Oct 24, 2023, 7:30 AM EDT - 2 years ago

InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

Sep 29, 2023, 1:21 PM EDT - 2 years ago

InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update

Sep 22, 2023, 6:15 PM EDT - 2 years ago

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

Sep 7, 2023, 8:30 AM EDT - 2 years ago

InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

Jul 21, 2023, 7:30 AM EDT - 2 years ago

InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET

Jul 20, 2023, 7:30 AM EDT - 2 years ago

InMed Provides Update on BayMedica Rare Cannabinoid Business

Jun 22, 2023, 7:30 AM EDT - 2 years ago

InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa

Jun 1, 2023, 7:30 AM EDT - 2 years ago

InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting

May 18, 2023, 5:00 PM EDT - 2 years ago

InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET

Bulltrader988 Sep. 6 at 8:43 PM

0 · Reply

Bulltrader988 Sep. 5 at 6:47 PM

$INM 👃👀 https://www.tipranks.com/news/company-announcements/inmed-pharmaceuticals-to-showcase-pipeline-progress-at-global-investment-conference?utm_source=webullapp.com&utm_medium=referral

0 · Reply

newsfile_corp Sep. 5 at 6:02 PM

https://nfne.ws/265322 $INM @inmedpharma #Alzheimer39s #cannabinoids #inm #inmed #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharma

0 · Reply

Bulltrader988 Sep. 5 at 5:56 PM

0 · Reply

Space0 Sep. 3 at 4:05 AM

$INM we need some good news

0 · Reply

ZURN999 Aug. 28 at 4:16 PM

$INM InMed presents INM-901 data at 2025 Alzheimer’s Association International Conference https://ow.ly/MZxg50WNfpr

0 · Reply

Cheriebomb Aug. 26 at 8:05 PM

$INM News?

0 · Reply

Bulltrader988 Aug. 22 at 6:20 PM

$INM when will we get new news? 👃👀

0 · Reply

mhaven2020 Aug. 19 at 2:21 PM

$CGTX $GDRX $INM $OPEN. here for the week at least.

1 · Reply

Space0 Aug. 19 at 6:58 AM

$INM Why are new tweets not showing up?

0 · Reply

MdcRaven13 Aug. 18 at 2:06 PM

$INM I imagine this one will heat up the higher that tilray and sundial go

0 · Reply

KKEE122 Aug. 18 at 3:09 AM

$INM According to my reading of the chart, I see that it is ready to launch $5 or more. I have informed you. Do not say that I have not informed you.

1 · Reply

SmartBetting Aug. 14 at 2:20 PM

$INM showtime is coming. goodluck.

0 · Reply

Space0 Aug. 14 at 1:15 PM

$INM smart money vibes right here 🚀 He clearly sees the massive upside in $INM — and I’m with him on this one

0 · Reply

aw20 Aug. 11 at 9:55 AM

$INM when this one runs, it runs hard 👀 loaded the dip for the next good news

0 · Reply

Space0 Aug. 11 at 9:07 AM

$INM unusual strength without headlines — the tape might be telling us that good news is just around the corner

0 · Reply

SuperFugazi Aug. 11 at 6:51 AM

$INM idiot

0 · Reply

Lolonaktie Aug. 7 at 8:53 AM

$INM It's at rock bottom. We need to push the stock up.

0 · Reply

aw20 Aug. 6 at 3:20 PM

$INM loaded again at 2.27. Expecting news soon 👀 NFA

0 · Reply

april1688 Aug. 6 at 1:41 PM

$INM how is inm now?

0 · Reply

Space0 Aug. 5 at 9:10 PM

$INM i think something good is going to happen 👀

0 · Reply

marketk Aug. 5 at 2:44 AM

$INM

0 · Reply

Market Cap	4.23M
Revenue (ttm)	4.60M
Net Income (ttm)	-7.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-166.96%
Debt to Equity Ratio	0.00

Volume	80,400
Avg Vol	97,672
Day's Range	N/A - N/A
Shares Out	2.00M
Stochastic %K	44%
Beta	0.29
Analysts	Strong Buy
Price Target	$45.00